Evidence map›Paper›PMID 41041036›Full record

ReviewJournal of current ophthalmology

Overcoming Resistance: A Comprehensive Review and Treatment Approach for Acyclovir-Resistant Herpes Simplex Keratitis.

Arash Mirzaei, Sahel Soltani Shahgoli, Raghuram Kognati, Emine Esra Karaca, Kasra Cheraqpour, Farhaneh Alahyari, Deepak Shukla, Ali R Djalilian, Mohammad Soleimani

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of current ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Arash MirzaeiEye Research Center, Department of Ophthalmology, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Sahel Soltani ShahgoliEye Research Center, Department of Ophthalmology, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Raghuram KognatiDepartment of Ophthalmology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Emine Esra KaracaDepartment of Ophthalmology, Ankara Numune Training and Research Hospital, Ankara, Turkey.
Kasra CheraqpourEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Farhaneh AlahyariSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Deepak ShuklaDepartment of Ophthalmology and Visual Sciences, University of Illinois Medical Center, Chicago, IL, USA.
Ali R DjalilianDepartment of Ophthalmology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Mohammad SoleimaniEye Research Center, Department of Ophthalmology, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To comprehensively review the treatment approach for acyclovir (ACV)-resistant herpes simplex keratitis (HSK). Methods: We thoroughly searched Web of Science, PubMed, and Scopus for relevant keywords and conducted this narrative review which explores the diagnosis of ACV-resistant HSK, and discusses alternative treatment strategies, reports previous cases. Results: Treatment strategies for ACV-resistant HSK include increasing ACV doses, switching to oral valacyclovir (VACV), and using topical antivirals such as foscarnet (FOS), ganciclovir (GCV), trifluridine, and cidofovir. Debridement of lesions and emerging antiviral agents are also considered. The review emphasizes the importance of diagnosing cytomegalovirus in ACV-resistant cases and explores new treatments like helicase primase inhibitors and BX795. Insights from the authors' clinical experience contribute to understanding ACV-resistant HSK and provide valuable guidance for clinicians managing this condition. Conclusions: HSK is a leading cause of ocular complications in HSV infections, potentially causing visual impairment. ACV has been the primary treatment, but rising ACV resistance necessitates alternative strategies. Options include increased ACV doses, oral VACV, topical FOS, GCV, interferon, and lesion debridement. Clinicians should also explore emerging treatments for ACV-resistant HSK.

Indexed as

AcyclovirAntiviral agentsFoscarnetGancyclovirHerpes simplex virusKeratitisPolymerase chain reaction

Identifiers

PMID41041036
PMCPMC12487793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.